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There is an inverse relationship between serum bilirubin concentrations and risk of coronary artery disease. The
strength of the association is similar to that of smoking, systolic blood pressure, and HDL cholesterol. We carried
out a genomewide scan in a Framingham Heart Study. Our study sample consisted of 330 families with 1,394
sibling pairs, 681 cousin pairs, and 89 avuncular pairs. Using variance-component methods, the heritability was
estimated to be 49%6%, and the genome scan demonstrated significant evidence of linkage of serum bilirubin
to chromosome 2q, with a LOD score of 3.8 at location 243 cM. The peak multipoint LOD score is located 1
cM away from the uridine diphosphate glycosyltransferase 1 (UGT1A1) gene. UGT1A1 catalyzes the conjugation
of bilirubin with glucuronic acid and thus enhances bilirubin elimination; therefore, it is an important candidate
gene for serum bilirubin. Gilbert syndrome, a hyperbilirubinemic syndrome, has a population frequency of 2%–19%
and is mainly due to a TA insertion at the promoter region of UGT1A1. Only one other region in the genome
produced a multipoint LOD score 11 (LOD p 1.3). Our findings suggest that UGT1A1 may be a major gene
controlling serum bilirubin levels in the population.
Recent studies, including a Framingham Offspring Study,
have shown that there is an inverse relationship between
serum bilirubin concentrations and risk of coronary ar-
tery disease (CAD) (Schwertner et al. 1994; Breimer et
al. 1995; Hopkins et al. 1996; Levinson 1997; Djousse
et al. 2001; Hunt et al. 2001). The strength of the as-
sociation with CAD was similar to that of smoking,
systolic blood pressure, and HDL cholesterol (Schwert-
ner 1998; Schwertner and Fischer 2000). Several studies
indicate bilirubin is an effective antioxidant that effi-
ciently scavenges peroxyl radicals; suppresses the oxi-
dation of lipids and lipoproteins, especially low density
lipoprotein; and thus acts against plaque formation and
subsequent atherosclerosis (Wu et al. 1991, 1996; Miller
et al. 1993; Lamont et al. 1997). Thus, there is increasing
interest in factors that regulate levels of serum bilirubin.
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Serum bilirubin is derived primarily from the degra-
dation of hemoglobin, catalyzed by heme oxygenase, and
is transported to the liver by binding to albumin. Within
hepatocytes, the solubility of bilirubin is increased by the
addition of one or two molecules of glucuronic acid,
catalyzed by UGT1A1 (MIM 191740). Bilirubin mon-
oglucuronide and diglucuronide metabolites are then ac-
tively transported into the bile.
In humans, the heritability of total serum bilirubin
has been estimated to be 58% (Williams et al. 1991).
Two segregation analyses in large population-based co-
horts have suggested that there is a major gene with the
rarer genotype associated with elevated bilirubin levels
(Hunt et al. 1996, 2001). Very recently, the authors of
a genome scan on serum bilirubin in a white population
ascertained by the presence of early CAD reported a locus
on chromosome 2q telomere, 2q34–37, that influences
variation in serum bilirubin levels (Kronenberg et al.
2002). Here, we report the results of a serum bilirubin
genome scan in unselected families, the Framingham
Heart Study.
The Framingham Heart study is a population-based
cohort study. In brief, the Framingham Heart Study be-
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Table 1
Characteristics of the 1,612 Framingham Offspring with Bilirubin Measured
VARIABLE
VALUE IN SUBJECTS
Male Female
Mean  SD Range Mean  SD Range
Total bilirubin (mg/dl) 8.8  3.8 2–35 7.1  2.9 2–27
Age (years) 32.3  10.4 11–64 33.3  10.5 10–62
Height (inches) 68.9  3.3 53–78 63.6  2.7 52–71
Weight (pounds) 176.1  29.4 54–264 137.1  27.8 67–281
Total cholesterol (mg/dl) 193.5  38.6 96–138 188.4  37.9 100–346
Hematocrit (%) 45.5  2.9 34–62 40.6  2.8 28–52
Albumin (mg/dl) 48.1  3.1 32–57 45.8  3.3 26–59
SGOTa (mg/dl) 47.9  20.0 18–221 40.4  17.7 8–285
Smoking (no./d) 15.0  16.4 0–90 11.0  14.1 0–88
Alcohol (oz./wk) 4.9  5.9 0–43 2.2  3.0 0–34
a Liver serum glutamic oxaloacetic transaminase.
Table 2
Markers with Two-Point LOD Score of 1 or Higher
Marker Chromosome
Location
(cM) LOD Score
D2S1363 2 227 1.7
D2S427 2 237 1.7
112yd2 2 261 1.5
D4S1647 4 105 1.2
D5S820 5 160 1.1
GATA118G10 7 79 1.4
gan in 1948 with the recruitment of 5,209 residents from
Framingham, MA. The subject individuals have under-
gone biennial examinations since the study began. In
1971, the Framingham Offspring Study (Kannel et al.
1979) was initiated. In total, there were 5,124 subjects
recruited. The offspring subjects have been examined
every 4 years (except the first two examinations, which
have 8 years intervening). The current analysis consists
of 1,702 genotyped subject individuals from the 330
largest extended families within the study.
Total serum bilirubin was measured during the first and
second examinations of the offspring, using the ultra-
micromethod (Walters and Gerarde 1970). Our analysis
was restricted to bilirubin measurements in the first ex-
amination, since far fewer individuals had serum bili-
rubin measured in the second examination. The corre-
lation coefficient between the two examinations is 0.6,
.P ! .01
Genomic DNAwas isolated from nucleated blood cells.
DNA samples were sent to the Marshfield Mammalian
Genotyping Service. At an average of 10 cM density, 399
microsatellite markers (Screening Set 8) (Yuan et al. 1997)
covered the genome with an average marker heterozy-
gosity of 0.77.
Variation in serum bilirubin due to known factors was
tested and removed, using SOLAR, to enhance the ability
of linkage analysis to detect genetically determined var-
iation (Almasy and Blangero 1998). The covariates se-
lected were all statistically significantly associated in a
regression model and were incorporated in both the her-
itability estimation and the linkage analysis. These were
sex, height, weight, total cholesterol, hematocrit, albu-
min, SGOT, smoking (no. of cigarettes/d), and alcohol
intake (oz./wk). At first, BMI (instead of height and
weight) was tested but was not significant in the multiple-
regression model. When BMI was replaced by height and
weight, both variables were highly significant. In essence,
SOLAR uses the residuals for heritability estimation and
two-point and multipoint linkage analysis. Further anal-
yses were conducted using normalized deviates. SOLAR
makes use of all information in pedigrees of any size
and structure. Residual heritability is the proportion of
total phenotypic variation due to additive genetic effects,
after removing the variation attributable to covariates.
Marker allele frequencies were estimated from the study
participants and then used to estimate the proportion of
alleles shared identical by descent (IBD) among all rel-
ative pairs. SOLAR uses a likelihood-ratio test to eval-
uate linkage by comparing a purely polygenic model
(without consideration of genetic marker information)
with a model that incorporates marker information at
a specific locus (two-point analysis) or several nearby
markers in a chromosome (multipoint analysis). We also
repeated the variance-components linkage analysis using
the normalized deviates, calculated from ranked stan-
dardized residuals in regression models conducted in SAS.
Since this method is based on the assumption of a mul-
tivariate normal distribution, violations of the assump-
tion may result in inflated type I error rates (Allison et
al. 1999; Blangero et al. 2000, 2001). To ensure a more
accurate result, we used an empirical P value method
implemented in SOLAR for LOD score adjustment
(Blangero et al. 2000). A fully informativemarker, which
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Figure 1 Maximum multipoint LOD scores for serum bilirubin for the 22 autosomes. X-axis values are the number of 22 autosomes. Y-
axis values are maximum multipoint LOD scores. Linkage analyses were conducted using multivariable residuals, adjusted for sex, height,
weight, total cholesterol, hematocrit, albumin, SGOT, smoking, and alcohol intake.
was not linked to the trait studied, was simulated. The
IBD information for this marker was calculated, and then
linkage analysis was performed. The empirical P values
for the trait were obtained on the basis of the LOD score
distribution generated from 10,000 replicates. This
method provides robust LOD scores for data with non-
normal distributions. As a second approach to account
for the nonnormality in these data, the analysis of nor-
malized deviates was also pursued.
There were 1,702 individuals in the 330 largest ex-
tended families who were genotyped. Among them, 394
individuals belonged to the original cohort and did not
have serum bilirubin measured. The total number of
individuals with serum bilirubin measured was 1,612.
The mean values of the phenotypes of the 1,612 (50%
male) individuals are displayed in table 1. The total num-
ber of individuals with serum bilirubin measured and
genotyped was 1,264, including 1,394 sibling pairs, 681
cousin pairs, and 89 avuncular pairs.
The distribution of serum bilirubin was not normal,
, and the estimates of skewness and kurtosis wereP ! .01
2.410.03 and 9.500.07, respectively, without co-
variates adjustment.
The heritability estimate from the serum bilirubin, af-
ter adjusting for covariates, was 49%6%. The pro-
portion of variance due to all final covariates is ∼11%.
For two-point linkage analysis, LOD scores of 1 or
higher were observed for markers on chromosomes 4,
5, and 7 and for three adjacent markers on chromosome
2 (table 2).
The highest multipoint LOD scores for each of the 22
autosomes are presented in figure 1. For multipoint anal-
ysis, a maximum LOD score of 3.8 ( ) wasPp .00001
observed on the chromosome 2q telomere, with the peak
location in 243 cM (fig. 2) with comprehensive human
genetic maps (Broman et al. 1998). Using normalized
deviates also produced very similar results, with a max-
imum LOD score of 3.9 located in 244 cM. We also
carried out a regular LOD score analysis without ad-
justing for nonnormality; a maximum LOD score of 5.7
was obtained at the same location, 2q 243 cM. Except
for this, there was only one region on chromosome 4
(96 cM) in the genome that had a maximum multipoint
LOD score 1 ( ).LODp 1.3
Peak evidence for linkage on chromosome 2 occurred
in the region bounded by markers D2S427 and
GATA178G09. The LOD-one supporting interval (the
region corresponding to maximum LOD score minus 1)
for the location of serum bilirubin QTL spans a 22-cM
interval flanked by markers D2S1363 and 112yd4,
which are 34 cM apart. The results provided substantial
evidence for a serum bilirubin QTL on 2q telomere.
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Figure 2 Multipoint LOD scores for serum bilirubin on chromosome 2. X-axis values are cM. Y-axis values are multipoint LOD scores.
Linkage analyses were conducted using multivariable residuals, adjusted for sex, height, weight, total cholesterol, hematocrit, albumin, SGOT,
smoking, and alcohol intake.
Our results are consistent with a recently reported ge-
nome scan, conducted in a population enriched for early-
onset cardiovascular disease, in which a locus with a
multipoint LOD score of 3.01 was identified in this re-
gion (Kronenberg et al. 2002). Thus, our finding com-
plement and extend the provocative findings of Kronen-
berg et al., conducted in a subset of families selected for
disease. Kronenberg et al. also provided evidence for loci
on chromosome 9, 10, and 18 that may possibly influ-
ence serum bilirubin levels. None of the loci on chro-
mosome 9, 10, and 18 overlap with our findings. In
addition to coming from a different study population,
the different results may be due to differences in linkage
analysis methods. Our study was conducted using em-
pirical P value and normalized deviate methods to adjust
LOD score for nonnormality of data, whereas Kronen-
berg et al. used both parametric and nonparametric link-
age methods without adjustment for nonnormality.With-
out adjustment for nonnormality, our results showed
at 2q, 243 cM.LODp 5.7
Within the chromosome region of 2q telomere lies an
important candidate gene, UGT1A1. This gene is ∼5Mb
(∼5 cM) telomeric from marker D2S427. The peak max-
imum LOD score in this area is located 6 cM telomeric
from marker D2S427. Therefore, UGT1A1 and the peak
maximum LOD score almost overlap. To date, no other
genes known to regulate serum bilirubinmetabolismhave
been found in this region.
Uridine diphosphoglucuronate glucuronosyltransfer-
ases (UGTs) are a family of enzymes that conjugate var-
ious substrates with glucuronic acid and enhance their
elimination through the bile. UGT1A1 is the physiolog-
ically relevant isoform and significantly contributes to
bilirubin glucuronidation. Mutations in UGT1A1 lead
to complete or partial inactivation of the enzyme, caus-
ing three nonhemolytic unconjugated hyperbilirubine-
mia syndromes, type I and type II Crigler-Najjar syn-
dromes and Gilbert syndrome. Crigler-Najjar syndromes
are rare and lethal forms of autosomal inherited diseases,
with a complete lack of bilirubin UGT activity (type I)
or a severe deficiency of the enzyme (type II). Type I and
type II Crigler-Najjar syndromes are mainly associated
with missense mutations in the coding region of the
UGT1A1 gene and have a frequency of 1 in 1 million
births. Gilbert syndrome, a more prevalent (2%–19%
in population studies) and essentially benign condition,
is principally caused by a TA insertion at the TATAA
promoter region upstream of the UGT1A1 exon. The
gene frequency of this mutation among the white pop-
ulation is extraordinarily high, 0.34–0.40 (Bosma et al.
1995; Monaghan et al. 1996; Beutler et al. 1998; Mor-
sche et al. 2001) and is very close to the estimated major
gene allele frequency from the two segregation analyses
(Hunt et al. 1996, 2001).
Combining the results of previous association and seg-
regation studies, the results of this genome scan, and the
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physiological function of the gene, we speculate that
UGT1A1 may be a major gene controlling serum bili-
rubin levels.
Two segregation studies indicated that a major gene
may protect ∼12% of the population against CAD, and
most individuals with CAD lacked the protective effect
from this gene associated with bilirubin levels (Hunt et
al. 1996, 2001). If12% of the population have a strong
protective effect against CAD owing to the UGT1A1
gene, this would have significant population implications
in future CAD prevention. Given the substantial mag-
nitude of variability in bilirubin explained by the chro-
mosome 2 region of linkage, our data support further
study of the role of the UGT1A1 gene variants in bili-
rubin determination and in risk for CAD and related
cardiovascular diseases.
In conclusion, our results provide evidence that a ma-
jor gene with a large effect influencing bilirubin levels
exists on chromosome 2q telomere. We have identified
a chromosomal region implicated in several Mendelian
hyperbilirubinemic disorders, and within this region re-
sides an important candidate gene, UGT1A1. Further
research is warranted to examine the linkage between
the UGT 1A1 gene and serum bilirubin levels, as well as
association studies to examine for associations of poly-
morphisms in the UGT1A1 gene with serum bilirubin and
CAD.
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